Arbutus Biopharma Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio

Company Highlights
Year Founded

1992

icon-altEmployees

72

Location (HQ)

USA

Since Last Funding

3 years

Monthly Website Visitors

8.0K

icon-altTotal Investment Amt

$400M

icon-altMoM Headcount Growth

-1.37%

icon-altYoY Headcount Growth

-19.98%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Pharmaceutical

Biotechnology

Medical

Biotechnology Research

Biopharma

Genetics